PranzatelliMRTateEDMcGeeNR. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology (“Tumor” vs. Pediatr Blood Cancer. 2018;65(8):e29721. doi:10.1002/pbc.27097.
2.
PatelAFischerCLinYC, et al. Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: the Memorial Sloan Kettering experience. Pediatr Blood Cancer. 2020;67(8):e28319. doi:10.1002/pbc.28319.
GormanMP. Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. Curr Opin Pediatr. 2010;22(6):745-750. doi:10.1097/MOP.0b013e32833fde3f.
5.
de AlarconPAMatthayKKLondonWB, et al. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018;2(1):25-34. doi:10.1016/S2352-4642(17)30130-X.
6.
BrunklausAPohlKZuberiSMde SousaC. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics. 2011;128(2):e388-e394. doi:10.1542/peds.2010-3114.
7.
PranzatelliMRTateEDMcGeeNR. Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol. 2017;8:468. doi:10.3389/fneur.2017.00468.
8.
MitchellWGWootenAAO’NeilSHRodriguezJGCruzREWitternR. Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS). J Child Neurol. 2015;30(8):976-982. doi:10.1177/0883073814549581.
